1
|
Bennet H, Balhuizen A, Medina A, Dekker Nitert M, Ottosson Laakso E, Essén S, Spégel P, Storm P, Krus U, Wierup N, Fex M. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 2015. [PMID: 26206285 DOI: 10.1016/j.peptides.2015.07.008] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Islet produced 5-hydroxy tryptamine (5-HT) is suggested to regulate islet hormone secretion in a paracrine and autocrine manner in rodents. Hitherto, no studies demonstrate a role for this amine in human islet function, nor is it known if 5-HT signaling is involved in the development of beta cell dysfunction in type 2 diabetes (T2D). To clarify this, we performed a complete transcriptional mapping of 5-HT receptors and processing enzymes in human islets and investigated differential expression of these genes in non-diabetic and T2D human islet donors. We show the expression of fourteen 5-HT receptors as well as processing enzymes involved in the biosynthesis of 5-HT at the mRNA level in human islets. Two 5-HT receptors (HTR1D and HTR2A) were over-expressed in T2D islet donors. Both receptors (5-HT1d and 5-HT2a) were localized to human alpha, beta and delta cells. 5-HT inhibited both insulin and glucagon secretion in non-diabetic islet donors. In islets isolated from T2D donors the amine significantly increased release of insulin in response to glucose. Our results suggest that 5-HT signaling participates in regulation of overall islet hormone secretion in non- diabetic individuals and over-expression of HTR1D and HTR2A may either contribute to islet dysfunction in T2D or arise as a consequence of an already dysfunctional islet.
Collapse
Affiliation(s)
- H Bennet
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - A Balhuizen
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - A Medina
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - M Dekker Nitert
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden; Royal Brisbane Clinical School, UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia
| | - E Ottosson Laakso
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - S Essén
- The Centre for Analysis and Synthesis, Department of Chemistry, Lund University, Getingevägen 60, SE-22241, Lund, Sweden
| | - P Spégel
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - P Storm
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - U Krus
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - N Wierup
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden
| | - M Fex
- Department of Clinical Science, Lund University Diabetes Centre, Scania University Hospital, Entrance 72, Clinical Research Centre House 91, Jan Waldenströmsgata 35, SE-20502, Malmö, Sweden.
| |
Collapse
|
2
|
Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain 2012; 153:830-838. [PMID: 22305629 DOI: 10.1016/j.pain.2012.01.005] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2011] [Revised: 12/21/2011] [Accepted: 01/06/2012] [Indexed: 10/14/2022]
Abstract
Triptans, a family of 5-hydroxytryptamine (5-HT) 1B, 1D, and 1F receptor agonists, are used in the acute treatment of migraine attacks. The site of action and subtypes of the 5-HT(1) receptor that mediate the antimigraine effect have still to be identified. This study investigated the mRNA expression of these receptors and the role of 5-HT(1) receptor subtypes in controlling the release of calcitonin gene-related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigeminal nucleus caudalis (TNC). The mRNA for each receptor subtype was quantified by quantitative real-time polymerase chain reaction. A high potassium concentration was used to release CGRP from dura mater, isolated TG, and TNC in vitro. The immunoreactive CGRP (iCGRP) release was measured by enzyme-linked immunoassay. The mRNA transcripts of the 3 5-HT(1) receptor subtypes were detected in the trigeminovascular system. Sumatriptan inhibited iCGRP release by 31% in dura mater, 44% in TG, and 56% in TNC. This effect was reversed by a 5-HT(1B/1D) antagonist (GR127395). The 5-HT(1F) agonist (LY-344864) was effective in the dura mater (26% iCGRP inhibition), and the 5-HT(1D) agonist (PNU-142633) had a significant effect in the TNC (48%), whereas the 5-HT(1B) agonist (CP-94253) was unable to reduce the iCGRP release in all tissues studied. We found that sumatriptan reduced the iCGRP release via activation of 5-HT(1D) and 5-HT(1F) receptor subtypes. The 5-HT(1F) receptor agonist was effective only in peripheral terminals in dura mater, whereas the 5-HT(1D) agonist had a preferential effect on central terminals in the TNC.
Collapse
MESH Headings
- Animals
- Calcitonin Gene-Related Peptide/antagonists & inhibitors
- Calcitonin Gene-Related Peptide/metabolism
- Dura Mater/drug effects
- Dura Mater/metabolism
- Gene Expression Regulation/drug effects
- Male
- RNA, Messenger/biosynthesis
- Rats
- Rats, Sprague-Dawley
- Receptor, Serotonin, 5-HT1B/biosynthesis
- Receptor, Serotonin, 5-HT1B/physiology
- Receptor, Serotonin, 5-HT1D/biosynthesis
- Receptor, Serotonin, 5-HT1D/physiology
- Receptors, Serotonin/biosynthesis
- Receptors, Serotonin/physiology
- Serotonin Receptor Agonists/pharmacology
- Trigeminal Ganglion/drug effects
- Trigeminal Ganglion/metabolism
- Trigeminal Nuclei/drug effects
- Trigeminal Nuclei/metabolism
- Receptor, Serotonin, 5-HT1F
Collapse
Affiliation(s)
- Dipak V Amrutkar
- Department of Neurology and Danish Headache Center, Glostrup Research Institute, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, USA
| | | | | | | | | | | |
Collapse
|
3
|
Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003; 23:10988-97. [PMID: 14645495 PMCID: PMC6740979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
Agonists at serotonin 1D (5-HT1D) receptors relieve migraine headache but are not clinically used as general analgesics. One possible explanation for this difference is that 5-HT1D receptors are preferentially expressed by cranial afferents of the trigeminal system. We compared the distribution of 5-HT1D receptor-immunoreactive (5-HT1D-IR) peripheral afferents within the trigeminal ganglion (TRG) and lumbar dorsal root ganglion (DRG) of the rat. We also examined the neurochemical identity of 5-HT1D-IR neurons with markers of primary afferent nociceptors, peripherin, isolectin B4, and substance P, and markers of myelinated afferents, N52 and SSEA3. We observed a striking similarity in the size, distribution, and neurochemical identity of 5-HT1D-IR neurons in TRG and lumbar DRG afferents. Furthermore, the vast majority of 5-HT1D-IR neurons are unmyelinated peptidergic afferents that distribute peripherally, including the dura, cornea, and the sciatic nerve. In the central projections of these afferents within the trigeminal nucleus caudalis and the spinal cord dorsal horn, 5-HT1D-IR fibers are concentrated in laminas I and outer II; a few axons penetrate to lamina V. At the ultrastructural level, 5-HT1D receptors in the spinal cord dorsal horn are localized exclusively within dense core vesicles of synaptic terminals. We observed scattered 5-HT1D-IR neurons in the nodose ganglia, and there was sparse terminal immunoreactivity in the solitary nucleus. The visceral efferents of the superior cervical ganglia did not contain 5-HT1D immunoreactivity. Our finding, that 5-HT1D receptors are distributed in nociceptors throughout the body, raises the possibility that triptans can regulate not only headache-associated pain but also nociceptive responses in extracranial tissues.
Collapse
Affiliation(s)
- Sonja Potrebic
- Department of Neurology, University of California, San Francisco, San Francisco, California 94143-0452, USA
| | | | | | | | | |
Collapse
|